# A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

> **NCT06365840** · PHASE2 · RECRUITING · sponsor: **ImmuneOncia Therapeutics Inc.** · enrollment: 30 (estimated)

## Conditions studied

- TMB-H
- Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors

## Interventions

- **DRUG:** IMC-001

## Key facts

- **NCT ID:** NCT06365840
- **Lead sponsor:** ImmuneOncia Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2029-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365840, "A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06365840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*